- Home
- ODFL vs ONC Comparison
ODFL vs ONC Comparison
Compare ODFL & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODFL
- ONC
- Stock Information
- Founded
- ODFL 1934
- ONC 2010
- Country
- ODFL United States
- ONC Switzerland
- Employees
- ODFL N/A
- ONC N/A
- Industry
- ODFL Trucking Freight/Courier Services
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- ODFL Industrials
- ONC Health Care
- Exchange
- ODFL Nasdaq
- ONC Nasdaq
- Market Cap
- ODFL 34.3B
- ONC 31.5B
- IPO Year
- ODFL 1991
- ONC N/A
- Fundamental
- Price
- ODFL $151.14
- ONC $321.36
- Analyst Decision
- ODFL Buy
- ONC Strong Buy
- Analyst Count
- ODFL 22
- ONC 9
- Target Price
- ODFL $171.00
- ONC $335.78
- AVG Volume (30 Days)
- ODFL 2.1M
- ONC 414.0K
- Earning Date
- ODFL 07-30-2025
- ONC 08-06-2025
- Dividend Yield
- ODFL 0.74%
- ONC N/A
- EPS Growth
- ODFL N/A
- ONC N/A
- EPS
- ODFL 5.12
- ONC N/A
- Revenue
- ODFL $5,638,622,000.00
- ONC $4,562,002,000.00
- Revenue This Year
- ODFL N/A
- ONC $865.19
- Revenue Next Year
- ODFL $7.71
- ONC $21.12
- P/E Ratio
- ODFL $29.52
- ONC N/A
- Revenue Growth
- ODFL N/A
- ONC 47.33
- 52 Week Low
- ODFL $140.91
- ONC $170.99
- 52 Week High
- ODFL $233.26
- ONC $321.69
- Technical
- Relative Strength Index (RSI)
- ODFL 46.07
- ONC N/A
- Support Level
- ODFL $140.91
- ONC N/A
- Resistance Level
- ODFL $153.55
- ONC N/A
- Average True Range (ATR)
- ODFL 4.77
- ONC 0.00
- MACD
- ODFL 0.40
- ONC 0.00
- Stochastic Oscillator
- ODFL 41.69
- ONC 0.00
About ODFL Old Dominion Freight Line Inc.
Old Dominion Freight Line is the second-largest less-than-truckload carrier in the United States (following FedEx Freight), with more than 250 service centers and 11,000-plus tractors. It is one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns are head and shoulders above its peers. Strategic initiatives revolve around boosting network density through market share gains and maintaining industry-leading service (including ultralow cargo claims) via steadfast infrastructure investment.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.